2024
The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024, 119: 1585-1596. PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patientsHigher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A, Shenoi S, Altice F. Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia. International Journal Of Drug Policy 2024, 126: 104369. PMID: 38484531, PMCID: PMC11056294, DOI: 10.1016/j.drugpo.2024.104369.Peer-Reviewed Original ResearchMethadone maintenance treatmentNational Institute of Drug AbuseMethadone dosePost-releaseOpioid dependenceMaintenance treatmentMethadone maintenance treatment doseHigher doses of methadoneProspective trialsHighest methadone dosagePost-release outcomesHigher methadone dosesMalaysia’s largest prison.Levels of depressionTreatment of opioid use disorderMonths of releaseDose of methadoneOpioid use disorderLargest prisonHigher dosageIncarcerated peopleIncarceration periodUse disorderMethadone dosageTime-to-event analysis
2021
Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationRelease
2013
Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug And Alcohol Dependence 2013, 132: 378-382. PMID: 23414931, PMCID: PMC3718876, DOI: 10.1016/j.drugalcdep.2013.01.005.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentMethadone doseKaplan-Meier survival analysisDose escalation procedureMethadone initiationThirty HIVMMT clinicsEvaluable participantsMaintenance treatmentOpioid dependenceMMT programSide effectsHigh dosesSurvival analysisHIVFirst weekPilot studyDoseMonthsTreatmentEscalation procedureDosesCravingParticipantsMonths of release
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatients